Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Results from two late-stage clinical trials show that tripling the standard dose of semaglutide can significantly increase weight loss in individuals with obesity, both with or without a type 2 diabetes diagnosis
This decision stemmed from Novo Nordisk's concerns regarding what it described as "illegal mass compounding and deceptive marketing" related to Hims & Hers' semaglutide offerings
Tracking numbers are issued at dispatch and visible in your account
Continued medical guidance ensures that progress remains safe, stable, and sustainable over time
US$ 25.16
US$ 24.58
US$ 22.26
US$ 26.85
